Mirati Therapeutics Inc (MRTX) Stock Falls -5.84% This Week: Is It a Good Pick?
Thursday, December 02, 2021 01:47 PM | InvestorsObserver Analysts
Mentioned in this article
Mirati Therapeutics Inc (MRTX) stock is down -41.29% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives MRTX stock a score of 21 out of a possible 100.
That rank is mainly influenced by a long-term technical score of 4. MRTX's rank also includes a short-term technical score of 12. The fundamental score for MRTX is 46. In addition to the average rating from Wall Street analysts, MRTX stock has a mean target price of $195.75. This means analysts expect the stock to rise 47.22% over the next 12 months.
MRTX has an Overall Score of 21. Find out what this means to you and get the rest of the rankings on MRTX!
Mirati Therapeutics Inc (MRTX) stock has gained 0.7% while the S&P 500 has gained 1.34% as of 1:46 PM on Thursday, Dec 2. MRTX has gained $0.92 from the previous closing price of $132.04 on volume of 235,034 shares. Over the past year the S&P 500 is higher by 24.66% while MRTX is down -41.29%. MRTX lost -$9.53 per share in the over the last 12 months.
Click Here to get the full Stock Report for Mirati Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
